CGA and pancreatic neuroendocrine tumor: (1)CART—marker for the identification of progressive pancreatic NETs; superior to CgA and CgB in detecting stable and progressive PCC or PGLs.(2)CART plasma levels decreased after resection of tumors, remained low in all patients in remission, but increased when progression of the disease occurred.(3)The measurement of CART did not improve diagnosis in gut, nonGEP NETs, and NETs with an unknown primary origin in comparison with combined CgA and CgB measurement.